TESCO ATHLETES FOOT CREAM, LLOYDS PHARMACY ATHLETES FOOT CREAM, CLOTRIMAZOLE 1% W/W CREAM, WILKO ATHLETES FOOT 1% W/W CREAM, SUPERDRUG ATHLETES FOOT 1% W/W CREAM - summary of medicine characteristics

1 NAME OF THE MEDICINAL PRODUCT

Lloydspharmacy Athletes Foot Cream

Clotrimazole 1% w/w cream

Tesco Athlete's Foot Cream

Superdrug Athlete’s Foot 1% w/w Cream

Wilko Athlete’s Foot 1% w/w Cream

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Clotrimazole 1% w/w

Excipient(s) with known effect:

Each 100 miligrams contains 1 mg benzyl alcohol.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Cream

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

For the treatment of tinea pedis (athlete’s foot)

4.2 Posology and method of administration

Dosage:

Adult, children and elderly:

Apply to the affected area two or three times daily.

Dermatophyte infections: treat for at least one month.

Route of administration:

Directly applied to the affected area.

A physician should be consulted if symptoms do not improve within 7 days

4.3 Contraindications

Known hypersensitivity to any of the components

Do not use the cream to treat nail or scalp infections.

4.4 Special warnings and precautions for use

Excipient(s)

Cetyl alcohol and stearyl alcohol

The cream contains cetyl alcohol and stearyl alcohol, which may cause local skin reaction (e.g. contact dermatitis)

Benzyl alcohol

Benzyl alcohol may cause allergic reactions.

Benzyl alcohol may cause mild local irritation.

4.5 Interaction with other medicinal products and other forms of interaction

None known

4.6 Pregnancy and lactation

Pregnancy

Data on a large number of exposed pregnancies indicate no adverse effects of Clotrimazole on pregnancy or on the health of the foetus/newborn child. To date, no other relevant epidemiological data are available.

Clotrimazole can be used during pregnancy, but only under the supervision of a physician or midwife.

Breastfeeding

It is unknown whether clotrimazole is excreted in breast milk, so it should be given with caution to lactating mothers.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

As the listed undesirable effects are based on spontaneous reports, assigning accurate frequency of occurrence for each is not possible.

Immune system disorders: allergic reaction (syncope, hypotension, dyspnoea, urticaria)

Skin and subcutaneous tissue disorders: blisters, discomfort/pain, oedema, irritation, peeling/exfoli­ation, pruritus, rash, stinging/burning.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at:

www.mhra.gov.uk/y­ellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

In the event of accidental oral ingestion, gastric lavage is rarely required and should be considered only if a life-threatening amount of clotrimazole has been ingested within the preceding hour or if clinical symptoms of overdose become apparent (e.g. dizziness, nausea or vomiting). It should be carried out only if the airway can be protected adequately.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

ATC code: D01A C01

Clotrimazole is an imidazole derivative with a broad spectrum of antimycotic activity. It also exhibits activity against Trichomonas, staphylococci, streptococci and Bacteroides. It has no effect on lactobacilli.

Mechanism of action

Clotrimazole acts against fungi by inhibiting ergosterol synthesis. Inhibition of ergosterol synthesis leads to structural and functional impairment of the cytoplasmic membrane.

Pharmacodynamic effects

Clotrimazole has a broad antimycotic spectrum of action in vitro and in vivo, which includes dermatophytes, yeasts, moulds, etc.

The mode of action of clotrimazole is fungistatic or fungicidal depending on the concentration of clotrimazole at the site of infection. In-vitro activity is limited to proliferating fungal elements; fungal spores are only slightly sensitive.

Primarily resistant variants of sensitive fungal species are very rare; the development of secondary resistance by sensitive fungi has so far only been observed in very isolated cases under therapeutic conditions.

5.2 Pharmacokinetic properties

Pharmacokinetic investigations after dermal application have shown that clotrimazole is minimally absorbed from the intact or inflamed skin into the human blood circulation. The resulting peak serum concentrations of clotrimazole were below the detection limit of 0.001 mcg/ml, suggesting that clotrimazole applied topically is unlikely to lead to measurable systemic effects or side effects.

5.3 Preclinical safety data

There are no preclinical data of reference to the prescriber which are additional to the information included in other sections of the SPC.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sorbitan stearate

Polysorbate 60

Cetyl Palmitate

Stearyl Alcohol

Cetyl Alcohol

2-Octyldodecanol

Benzyl Alcohol

Purified Water

6.2 Incompatibilities

None known.

6.3 Shelf life

36 months.

6.4 Special precautions for storage None.

6.5 Nature and contents of container

Aluminium tube with polypropylene screw-on cap containing 20/30/50g of cream.

6.6 Special precautions for disposal None.

7 MARKETING AUTHORISATION HOLDER

Teva UK Limited

Brampton Road

Hampden Park

Eastbourne

East Sussex

BN22 9AG

8 MARKETING AUTHORISATION NUMBER(S)

PL 00289/1643

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

27 January 1998